
Linda R Duska MD
Gynecologic Oncology, Hospice & Palliative Medicine
Professor of Obstetrics & Gynecology, University VA School of Medicine
Join to View Full Profile
1240 Lee StCharlottesville, VA 22908
Phone+1 434-924-9333
Fax+1 434-244-7526
Dr. Duska is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Mass General Brigham/Massachusetts General HospitalFellowship, Gynecologic Oncology, 1995 - 1998
- Johns Hopkins UniversityResidency, Obstetrics and Gynecology, 1991 - 1995
- New York University School of MedicineClass of 1991
Certifications & Licensure
- VA State Medical License 2008 - 2026
- FL State Medical License 2019 - 2021
- MA State Medical License 1995 - 2012
- American Board of Internal Medicine Hospice and Palliative Medicine
- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2012-2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- America's Top Doctors for Cancer Castle Connolly, 2011-2013
- Join now to see all
Clinical Trials
- Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma Start of enrollment: 2006 Feb 01
- Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2009 Oct 28
- Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Apr 05
- Join now to see all
Publications & Presentations
PubMed
- Endometrial cancer decades after supracervical hysterectomy for placenta accreta spectrum: A case report.Lauren T Gilgannon, Linda R Duska
Gynecologic Oncology Reports. 2025-06-01 - The BEV1L study: Do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial...Linda R Duska, Jonathan Lim, Tirza Areli Calderón Boyle, Mark Guinter, Siobhan Halloran
Cancer. 2025-05-15 - 1 citationsGenomic alterations, molecularly targeted therapy, and survival: a real-world Endometrial Cancer Molecularly Targeted Therapy Consortium cohort study.Angeles Alvarez Secord, Victoria Bae-Jump, Floor Backes, Premal Thaker, Paola A Gehrig
International Journal of Gynecological Cancer. 2025-05-01
Press Mentions
- Adding Bevacizumab to Chemo Beneficial in High-Risk Ovarian CancerMay 13th, 2025
- Bevacizumab Ovarian Cancer Trial: Real-World Impact?May 13th, 2025
- Adding Bevacizumab to Chemo Beneficial in High-Risk Ovarian CancerMay 13th, 2025
- Join now to see all
Professional Memberships
- Member
- Fellow
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: